Immix Biopharma Inc.

Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank

8:45 p.m. March 10, 2023

- GlobeNewswire

Nexcella to Discuss Recent Positive NXC-201 Clinical Data In AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14

9:05 a.m. March 6, 2023

- GlobeNewswire

ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14

9:00 a.m. March 6, 2023

- GlobeNewswire

Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission

9:50 a.m. Feb. 27, 2023

- GlobeNewswire

Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission

9:45 a.m. Feb. 27, 2023

- GlobeNewswire

Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.

9:35 a.m. Feb. 15, 2023

- GlobeNewswire

Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.

9:30 a.m. Feb. 15, 2023

- GlobeNewswire

Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting

9:05 a.m. Feb. 9, 2023

- GlobeNewswire

Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting

9:00 a.m. Feb. 9, 2023

- GlobeNewswire

Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer

9:00 a.m. Feb. 7, 2023

- GlobeNewswire

Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

9:00 a.m. Jan. 13, 2023

- GlobeNewswire

Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached

9:05 a.m. Jan. 6, 2023

- GlobeNewswire

Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached

9:00 a.m. Jan. 6, 2023

- GlobeNewswire

Nexcella, Inc announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting

9:05 a.m. Dec. 28, 2022

- GlobeNewswire

Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting

9:00 a.m. Dec. 28, 2022

- GlobeNewswire

Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

9:00 a.m. Dec. 20, 2022

- GlobeNewswire

ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors

9:00 a.m. Dec. 19, 2022

- GlobeNewswire

Thinking about buying stock in Panbela Therapeutics, SoFi Technologies, Immix Biopharma, Plug Power, or Carvana?

12:34 p.m. Dec. 14, 2022

- PR Newswire - PRF

Nexcella, Inc. in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)

9:05 a.m. Dec. 14, 2022

- GlobeNewswire

Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)

9:00 a.m. Dec. 14, 2022

- GlobeNewswire